Skip to main navigation Skip to search Skip to main content

Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis

  • Christine Hale
  • , Frances Bowe
  • , Derek Pickard
  • , Simon Clare
  • , Jean Francois Haeuw
  • , Ultan Powers
  • , Nathalie Menager
  • , Pietro Mastroeni
  • , Gordon Dougan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Immunisation of BALB/c mice with a vaccine containing Vi polysaccharide conjugated to the Klebsiella pneumoniae outer membrane 40 kDa protein (rP40), in combination with Escherichia coli heat-labile toxin adjuvant (LT), elicited anti-Vi IgG antibodies after administration using different routes. Testing of the immune serum in opsonisation assays demonstrated the specific enhancement of Vi-positive bacterial uptake by cultured murine bone marrow derived macrophages. Intra-peritoneal challenge of mice immunised with the Vi-based vaccine elicited a degree of protection against virulent Vi+ Salmonella enterica serovar typhimurium (S. typhimurium). In contrast, Vi vaccination did not confer protection against oral challenge with virulent Vi-positive S. typhimurium or S. dublin.

Original languageEnglish
Pages (from-to)4312-4320
Number of pages9
JournalVaccine
Volume24
Issue number20
DOIs
Publication statusPublished - 15 May 2006
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antibody
  • Salmonella
  • Typhoid
  • Vaccination
  • Vi polysaccharides

Cite this